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Abstract. 
 
Lipoprotein transport across the blood–brain 
barrier (BBB) is of critical importance for the delivery 
of essential lipids to the brain cells. The occurrence of a 
low density lipoprotein (LDL) receptor on the BBB 
has recently been demonstrated. To examine further 
the function of this receptor, we have shown using an in 
vitro model of the BBB, that in contrast to acetylated 
LDL, which does not cross the BBB, LDL is specifi-
cally transcytosed across the monolayer. The C7 mono-
clonal antibody, known to interact with the LDL recep-
tor-binding domain, totally blocked the transcytosis of 
LDL, suggesting that the transcytosis is mediated by 
the receptor. Furthermore, we have shown that choles-
terol-depleted astrocytes upregulate the expression of 
the LDL receptor at the BBB. Under these conditions, 
we observed that the LDL transcytosis parallels the in-
crease in the LDL receptor, indicating once more that 
the LDL is transcytosed by a receptor-mediated mech-
anism. The nondegradation of the LDL during the 
transcytosis indicates that the transcytotic pathway in 
brain capillary endothelial cells is different from the 
LDL receptor classical pathway. The switch between a 
recycling receptor to a transcytotic receptor cannot be 
explained by a modification of the internalization sig-
nals of the cytoplasmic domain of the receptor, since we 
have shown that LDL receptor messengers in growing 
brain capillary ECs (recycling LDL receptor) or differ-
entiated cells (transcytotic receptor) are 100% identi-
cal, but we cannot exclude posttranslational modifica-
tions of the cytoplasmic domain, as demonstrated for 
the polymeric immunoglobulin receptor. Preliminary 
studies suggest that caveolae are likely to be involved in 
the potential transport of LDL from the blood to the 
brain.
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1. 
 
Abbreviations used in this paper
 
: acLDL, acetylated LDL; BBB, blood–
brain barrier; EC, endothelial cell; LDL, low density lipoprotein.
 
T
 
he
 
 maintenance of the homeostasis of brain inter-
stitial fluid, which constitutes the special microenvi-
ronment for neurons, is established by the presence
of the blood–brain barrier (BBB)
 
1
 
 at the transition area
from endothelial cells (ECs) to brain tissue. Of primary
importance in the formation of a permeability barrier by
these cells is the presence of continuous tight junctions
that seal together the margins of the ECs and restrict the
passage of substances from the blood to the brain. Fur-
thermore, in contrast to ECs in many other organs, the
brain capillary ECs contain no direct transendothelial pas-
sageways such as fenestrations or channels. But obviously,
the BBB cannot be absolute. The brain is dependent upon
the blood to deliver metabolic substrates and remove met-
abolic waste, and the BBB therefore facilitates the ex-
change of selected solutes. Carrier-mediated transport sys-
tems that facilitate the uptake of hexoses, amino acids,
purine compounds, and mono-carboxylic acids have been
revealed in the cerebral endothelium (Betz and Goldstein,
1978), but until now little information has come to light re-
garding the cerebral uptake of lipids.
There is growing evidence that the brain is equipped
with a relatively self-sufficient transport system for main-
taining cholesterol and lipid homeostasis. The presence of
a low density lipoprotein (LDL) receptor has been dem-
onstrated by immunocytochemistry in rat and monkey
brains; and apolipoprotein (apo) E and apo AI-containing
particles have been detected in human cerebrospinal fluid
(Pitas et al., 1987). Furthermore, enzymes involved in lipid
metabolism have been located within the brain: LCAT
mRNA has been shown to be expressed in rat brains and
cholesteryl ester transfer protein, which plays a key role in
cholesterol homeostasis, has been detected in human cere-
brospinal fluid and seems to be synthesized in the brain
(Albers et al., 1992). The distribution of the LDL recep-
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tor-related protein, a multifunctional receptor that binds
apoE, is highly restricted and limited to the gray matter,
primarily associated with neuronal cell population (Wolf
et al., 1992). The difference in cellular expression of ligand
(apoE) and receptor (LDL receptor-related protein) may
provide a pathway for intracellular transport of apoE-con-
taining lipoproteins in the central nervous system. All
these data leave little doubt that the brain is equipped with
a relatively self-sufficient transport system for cholesterol.
Cholesterol could be derived from de novo synthesis
within the brain and from plasma via the BBB. Malavolti
et al. (1991) indicate the presence of unexpectedly close
communications between extracerebral and brain choles-
terol. Changes in the extracerebral cholesterol levels are
readily sensed by the LDL receptor in the brain and
promptly provoke appropriate modifications in its activity.
Méresse et al. (1989
 
a
 
) provided direct evidence for the oc-
currence in vivo of an LDL receptor on the endothelium
of brain capillaries. Furthermore, the fact that enzymes in-
volved in the lipoprotein metabolism are present in the
brain microvasculature (Brecher and Kuan, 1979) and that
the entire fraction of the drug bound to lipoproteins is
available for entry into the brain strongly suggest that this
cerebral endothelial receptor plays a role in the interac-
tion of plasma lipoproteins with brain capillaries. These
results pinpoint the critical importance of the interactions
between brain capillary ECs and lipoproteins. Owing to
the fact that the neurological abnormalities that result
from the inadequate absorption of dietary vitamin E can
be improved by the oral administration of pharmacologi-
cal doses of vitamin E, Traber and Kayden (1984) have
suggested that LDL functions as a transport system for to-
copherol to the brain. Furthermore, the trace amounts of
apolipoprotein B that were detected by Salem et al. (1987)
in cerebrospinal fluid from healthy patients using a very
sensitive immunoblot technique confirm that, at most,
small amounts of apolipoprotein B normally pass through
the BBB. However, whether LDL is involved in the ex-
change is not known.
Using an in vitro model of the BBB that imitates an in
vivo situation by culturing capillary ECs and astrocytes on
opposite sides of a filter (Dehouck et al., 1990
 
a
 
, 1992), we
have demonstrated that in culture, like in vivo, in contrast
to peripheral endothelium and in spite of the tight apposi-
tion of ECs and their contact with physiological concentra-
tions of lipoproteins, brain capillary ECs express an LDL
receptor (Méresse et al., 1991; Dehouck et al., 1994). The
capacity of ECs to bind LDLs is greater when cocultured
with astrocytes than in their absence. Futhermore, we
have shown that the lipid requirement of astrocytes in-
creases the expression of the LDL receptor on brain capil-
lary ECs. Taken together, the presence of LDL receptors
on brain capillary ECs and the modulation of the expres-
sion of these receptors by the lipid composition of astro-
cytes suggest that cholesterol used by cells in the central
nervous system may be derived, at least in part, from the
periphery via transport across the BBB.
In the present study, we provide direct evidence that af-
ter binding to brain capillary ECs, there is a specific mech-
anism for the transport of LDL across the endothelial
monolayer from the apical to the abluminal surface. This
mechanism might be best explained by a process of recep-
 
tor-mediated transcytosis. Preliminary results pinpoint the
role of caveolae in the transcellular transport of LDL
across the brain endothelium.
 
Materials and Methods
 
Cell Culture
 
Bovine Brain Capillary ECs. 
 
Brain capillary ECs were isolated and charac-
terized as described by Méresse et al. (1989
 
b
 
). The use of cloned endothe-
lial cells allows the obtainment of a pure endothelial cell population with-
out contamination by pericytes. The cells were cultured in the presence of
DME supplemented with 15% (vol/vol) heat-inactivated calf serum (Hy-
clone Laboratories, Logan, UT), 2 mM glutamine, 50 
 
m
 
g/ml gentamycin,
and bFGF [basic fibroblast growth factor]; 1 ng/ml, added every other
day).
 
Bovine Adrenal Cortex Endothelial Cells (ACE). 
 
ACE were isolated and
characterized as described by Gospodarowicz et al. (1986). ACE (a gift
from Dr. S. Saule, Institut Pasteur, Lille, France) were cultured like the
bovine brain capillary ECs.
 
Rat Astrocytes. 
 
Primary cultures of mixed astrocytes were made from
newborn rat cerebral cortex. After the meninges had been removed, the
brain tissue was gently forced through a nylon sieve, as described by Boo-
her and Sensenbrenner (1972). Astrocytes were plated on six multiwell
dishes (Nunclon; Nunc A/S, Roskilde, Denmark) at a concentration of 1.2
 
3
 
 10
 
5
 
 cells/ml in 2 ml of DME supplemented with 10% FCS (Hyclone Lab-
oratories), and the medium was changed twice a week. 3 wk after seeding,
cultures of astrocytes were stabilized and used for experiments. The astro-
cytes were characterized with glial fibrillary acidic protein (GFAP), and
 
.
 
95% of the population was GFAP positive (Dehouck et al., 1990
 
b
 
).
 
Coculture of Endothelial Cells and Astrocytes. 
 
Preparation of filters for
coculture: culture plate inserts (Millicell-CM 0.4 
 
m
 
m; 30-mm diam; Milli-
pore Corp., Milford, MA) were coated on the upperside with rat-tail col-
lagen prepared by a modification of the method of Bornstein (1958).
Experimental method: cultures of astrocytes were prepared as de-
scribed above. After 3 wk, coated filters were set in six multiwell dishes
containing astrocytes, and ECs were plated on the upperside of the filters
in 1.5 ml of medium with a concentration of 4 
 
3
 
 10
 
5
 
 cells/ml for bovine
brain capillary ECs and adrenal cortex ECs. The medium used for the co-
culture was DME supplemented with 15% CS, 2 mM glutamine, 50 
 
m
 
g/ml
gentamycin, and 1 ng/ml bFGF. This medium was changed every other
day. Under these conditions, ECs form a confluent monolayer after 7 d.
Experiments were performed 5 d after confluence.
 
Fluorescence Microscopy
 
Endothelial cells grown on porous filters were fixed at room temperature
for 20 min with 4% paraformaldehyde in a fibrous component-stabilizing
buffer (PHEMS; 60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 2 mM
MgCl
 
2
 
, and 140 mM NaCl, pH 6.9). After being washed in PHEMS, the
cells on filter fragments were permeabilized with cold acetone (
 
2
 
20
 
8
 
C)
for 10 min, followed by two washes with PHEMS. Cells were then stained
with filamentous actin probe, bodipy–phallacidin (Molecular Probes, Inc.,
Eugene, OR; 165 nM, 30 min, at room temperature). Mitotracker CMX
Ros coloration was carried out as indicated by the manufacturer (Molecu-
lar Probes, Inc). For the localization of tight junction-associated protein
ZO-1 to the plasma membrane, the cells were fixed with cold methanol
(
 
2
 
20
 
8
 
C). Fixed cells were incubated with an affinity-purified rabbit anti–
ZO-1 (Zymed Labs., S. San Francisco) diluted in Tris-HCl–buffered saline
(20 mM Tris-HCl, 0.5 M NaCl, pH 7) containing 5% (wt/vol) ovalbumin
and 1% heat-inactivated normal goat serum. Subsequently, the cells were
incubated for 1 h at room temperature with the appropriate combination
of fluorescently labeled secondary antibodies and propidium iodine (2 
 
m
 
g/
ml). For the luminal uptake of DiI (0,1
 
9
 
-dioctadecyl-3,3,3
 
9
 
,3
 
9
 
-tetramethyl-
indocarbocyanine percholate)-LDL, the ECs were incubated for 45 min at
37
 
8
 
C in prewarmed DME, 5% LPDS (lipoprotein deficient serum) with
DiI-LDL (35 
 
m
 
g/ml). The inhibition of DiI-LDL uptake was performed in
the presence of filipin. The cells were pretreated with 3 
 
m
 
g/ml filipin for 10
min at 37
 
8
 
C, washed, and incubated with DiI-LDL. In the case of the
study of the reversibility of filipin treatment effect, ECs were incubated
for 1 h at 37
 
8
 
C in serum-containing medium before the addition of DiI-
LDL. All incubations were terminated by three washes in ice-cold Pipes–
Hepes buffer and immediately fixed with 4% paraformaldehyde.
After the final washes, the filters and their attached monolayers were 
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mounted on glass microscope slides using Mowiol mountant (Hoechst,
Frankfurt, Germany) containing 
 
p
 
-phenylene diamine (0.1%, Sigma Chem-
ical Co., St. Louis, MO) anti-quenching agent. All specimens were studied
using a fluorescence microscope, (DMRB; Leica Mikroskopie und Systeme
GmbH, Wetzlar, Germany), and pictures were taken on Kodak Tmax film.
 
Preparation of Low Density Lipoproteins, Acetylated 
LDL, and Lipoprotein-deficient Serum
 
LDL was isolated from human plasma by sequential ultracentrifugation at
the densities of 1.03–1.053. The densities were adjusted using solid KBr.
The LDL was extensively dialyzed at 4
 
8
 
C against 0.15 M NaCl. Acetylated
LDL was prepared by treating LDL with acetic anhydride (Basu et al.,
1976). LDL was radioiodinated as described by Bilheimer et al. (1972).
After labeling, the LDL was chromatographed on a PD10 column (Phar-
macia Fine Chemicals, Piscataway, NJ) and extensively dialyzed at 4
 
8
 
C
against 0.15 M NaCl and 0.01% EDTA (pH 7.4). The specific activity of
 
125
 
I-LDL, which was used within 10 d of preparation, ranged from 300 to
400 cpm/ng protein. LPDS was prepared from calf serum by ultracentrifu-
gation at the density of 1.25 adjusted with solid KBr. LPDS was exten-
sively dialyzed at 4
 
8
 
C against DME.
 
Preparation of Fluorescently Labeled Lipoprotein and 
Lipoprotein–Gold Complex
 
The fluorescent probe chosen is DiI (1,1
 
9
 
-dioctadecyl-3,3,3
 
9
 
,3
 
9
 
-tetra-
methyl-indocarbocyanine percholate). The lipoprotein concentration
should be between 1 and 2 mg lipoprotein/ml in saline–EDTA. 2 ml of li-
poprotein-deficient serum is added to each 1 mg of lipoprotein to be la-
beled with DiI. The solution is then filtered (0.45 
 
m
 
m for LDL) through
Millex-PF filters. The solution is gently shaken, and 50 
 
m
 
l of DiI in DMSO
(3 mg/ml) is added per mg of lipoprotein. The mixture is incubated for 15–
20 h at 37
 
8
 
C. The LDLs are reisolated from the incubation mixture by ul-
tracentrifugation at the density of 1.063. The density of 1.063 is obtained
by adding 0.0834 
 
g
 
 of KBr for each ml of incubation mixture. LDLs are re-
isolated using a four-rotor centrifuge (TL100; Beckman Instr., Fullerton,
CA) at 100,000 rpm for 2 h at 10
 
8
 
C. After centrifugation, the LDLs are di-
alyzed against saline–EDTA.
Freshly isolated LDL with 16-nm colloidal gold was labeled according
to the method of Handley et al. (1981).
 
125
 
I-LDL and 
 
125
 
I–acLDL Binding
 
ECs were incubated for 2 h at 4
 
8
 
C with DME, 10 mM Hepes, 0.2% BSA,
and 35 
 
m
 
g/ml of 
 
125
 
I-LDL and 
 
125
 
I–acLDL were added in the upper or
lower compartment
 
.
 
 At the end of the incubation, the cells were washed
nine times at 4
 
8
 
C: three times with 4 ml of PBS (Ca
 
2
 
1
 
/Mg
 
2
 
1
 
); three times
with 4 ml of PBS (Ca
 
2
 
1
 
/Mg
 
2
 
1
 
) containing 0.2% BSA; three times with 4 ml
of PBS (Ca
 
2
 
1
 
/Mg
 
2
 
1
 
). EC-associated radioactivity was then determined by
removing the membrane of the culture insert and counting it in a 
 
g
 
counter. Nonspecific binding was determined by incubating the cells with
 
125
 
I-lipoproteins and a 20-fold excess of unlabeled related lipoproteins.
Binding is expressed in ng/cm
 
2
 
, since one filter of 4.2 cm
 
2
 
 represents 90 
 
m
 
g
of cellular protein.
 
Studies of Lipoprotein Transport Through Brain 
Capillary EC Monolayers
 
Passage of 
 
125
 
I-LDL or Acetylated 
 
125
 
I-LDL through Brain Capillary EC
Monolayers. 
 
The passage of lipoproteins through brain capillary EC
monolayers was studied using the coculture model, as described above.
ECs seeded on collagen-coated filters were cultured with astrocytes for 12 d.
Each filter was then transferred to a six multiwell dish containing 2 ml of
DME with 15% LPDS (lower compartment). At time zero, a known
amount of the iodinated lipoprotein (usually 35 
 
m
 
g protein/ml) in DME
with 15% LPDS was added on the luminal face of an EC monolayer (up-
per compartment; 700 
 
m
 
l). During the experiments, the monolayers were
kept at 37
 
8
 
C. At several time points, filters were transferred to the next
well. At the end of the experiment, all lower and upper compartments
were collected. Precipitation of samples by trichloroacetic acid was per-
formed. The determination of the total 
 
125
 
I-LDL passage was performed
by counting, in a 
 
g
 
 counter, the acid-precipitable fractions of the lower
compartments. Nonspecific passage was determined by incubating the
cells with 
 
125
 
I-LDL and a 20-fold excess of unlabeled LDL. Specific trans-
port was calculated by subtracting the nonspecific from the total transport.
 
Passage rates were expressed in ng LDL/cm
 
2
 
. The filter permeability to
LDL was carried out with collagen-coated filters.
 
Degradation of 
 
125
 
I-LDL or Acetylated 
 
125
 
I-LDL during the Transcytosis.
 
For the determination of the degradation of LDLs during their passage (5 h)
through EC monolayers, acid-soluble fractions from upper and lower
compartment samples were separated by centrifugation from acid-precipi-
table fractions; AgNo
 
3
 
 (5%) precipitation was then performed to correct
for free 
 
125
 
I. AgNo
 
3
 
-soluble fractions were counted in a 
 
g
 
 counter. Non-
specific degradation was determined by incubating the cells with 
 
125
 
I-LDL
and a 20-fold excess of unlabeled LDL. Total degradation was corrected
for nonspecific flux giving the specific LDL degradation. Degradation
rates are expressed in ng LDL/mg cell protein.
 
Degradation of Transcytosed 
 
125
 
I-LDL by Astrocytes. 
 
The degradation of
transcytosed 
 
125
 
I-LDL by astrocytes was performed using the coculture
situation. 1 ml of medium containing 35 
 
m
 
g of labeled LDL was added in
the upper compartment and 2.5 ml of medium containing 10% LPDS in
the lower one. The coculture (i.e., ECs and astrocytes) was kept at 37
 
8
 
C
for 16 h. Degradation was carried out as described above. Nonspecific
degradation was determined by adding 3 
 
m
 
g of unlabeled LDL in the
lower compartment, which represents a 10-fold excess owing to the pas-
sage of 
 
z
 
100 ng for 5 h/cm
 
2
 
. Control experiments were carried out with
ECs separated from astrocytes.
 
Effect of Temperature on 
 
125
 
I-LDL Transport. 
 
The 
 
125
 
I-LDL transport ex-
periments were performed as described above, but the monolayers were
kept at 4
 
8
 
C.
 
Inhibition of 
 
125
 
I-LDL Passage through Brain Capillary ECs. 
 
ECs were incu-
bated for 15 min with different concentrations (1 and 0.1 mg/ml) of the
monoclonal antibody designated immunoglobulin C-7 (American Type
Culture Collection, Rockville, MD; Beisiegel et al., 1981) and with or
without unlabeled LDL (upper compartment). 
 
125
 
I-LDL was then added
to this compartment, and the rate of LDL passage was determined as de-
scribed above. Irrelevant IgGs directed against apolipoprotein AI (1 mg/
ml) were used as a control.
 
Modulation of the Transcytosis by the Lipid Composition of Astrocytes.
 
The induction of LDL receptor expression (Dehouck et al., 1994) can be
described in four phases: (
 
a
 
) coculture phase; brain capillary ECs and as-
trocytes were cocultured for 12 d in DME supplemented with 15% CS as
described above. (
 
b
 
) Astrocyte LPDS phase; ECs were transferred and
cocultured with other astrocytes in fresh DME supplemented with 15%
calf serum. Astrocytes of the original coculture were incubated for 36 h at
37
 
8
 
C with DME supplemented with 10% LPDS, 2 mM glutamine, and 50
 
m
 
g/ml gentamycin. As a control, astrocytes were incubated with DME
supplemented with 10% FCS. (
 
c
 
) Induction phase; on the day of the ex-
periment, the filter inserts with ECs, in 1.5 ml of fresh DME supple-
mented with 15% calf serum, were moved to a well that contained astro-
cytes in their 36-h LPDS conditioned medium. The cells were incubated
together for different times at 37
 
8
 
C. (
 
d
 
) LDL binding phase after the “in-
duction phase,” 
 
125
 
I-LDL bindings to ECs at 4
 
8
 
C, 
 
125
 
I-LDL transport, and
DiI-LDL uptake experiments at 37
 
8
 
C were performed as described above.
 
Electron Microscopy Studies. 
 
After incubation at different times with
gold–LDL or horseradish peroxidase, the cells were fixed routinely with
2.5% glutaraldehyde in sodium cacodylate buffer, pH 7.2, at 4
 
8
 
C and post-
fixed in 1% OsO
 
4
 
 for 60 min. After being dehydrated in ethanol and em-
bedded in araldite, sections perpendicular to the monolayer-cultured cells,
contrasted with lead hydroxide, were examined with an electron micro-
scope (420; Philips, Eindhoven, The Netherlands).
 
Sequencing of the LDL Receptor Cytoplasmic Domain 
Involved in the Basolateral Targeting
 
RNA Extraction. 
 
Total cell RNA was obtained from growing brain capil-
lary ECs, differentiated brain capillary ECs depleted or not in cholesterol,
or aortic ECs, using the guanidium-thiocyanate chloride procedure ac-
cording to Sambrook et al. (1989).
 
RT-PCR. 
 
5 
 
m
 
g of total RNA was reverse transcribed by 50 U of
MMLV-reverse transcriptase (Stratagene, La Jolla, CA) in a total volume
of 50 
 
m
 
l containing 100 
 
m
 
M of each dNTP, 100 ng of oligod(T)12-18, 20 U
Rnasin (Promega, Madison, WI), and 10 mM dithiothreitol for 1 h at 37
 
8
 
C.
After reverse transcription, samples were heated at 95
 
8
 
C for 5 min to de-
nature the MMLV-RT and then held at 
 
2
 
20
 
8
 
C until PCR.
To perform PCR, specific internal primer pairs for the bovine LDL re-
ceptor were designed using the published sequence (Russel et al., 1984)
and the Primer Premier version 3.1 software (Biosoft International, Palo
Alto, CA). Primer sequences were as follows: BLDLR1: 5
 
9
 
 GAGCGT-
GGGTGCCCTATACA 3
 
9
 
 and BLDLR2: 5
 
9
 
 GGACTCAAGGCAGCA- 
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GCTCA 3
 
9
 
. PCR amplification was carried out using a thermal cycler
(Maxicycler PT-100
 
TM
 
; MJ Research, Watertown, MA). 50 ml of reaction
mixture contained 5 ml of first strand DNA, buffer (10 mM Tris-HCl, pH
8), MgCl2 (1.5 mM), dNTPs (40 mM), primers (0.4 mM), and 1.5 U Taq
polymerase (Eurogentec, Seraing, Belgium). The amplification profile
was 94°, 55°, and 728C each for 1 min times 30 cycles, preceded by 5 min at
948C and followed by 7 min at 728C to ensure completion of extension. To
check for contamination, PCR in the absence of DNA was used as a nega-
tive control.
Sequencing. The PCR products were visualized on ethidium bromide-
stained agarose gels after electrophoresis and sequenced on both strands
by an Aby prism dye terminator cycle sequencing kit on an automatic se-
quencer (ABI-377; Applied Biosystems, Foster City, CA).
Results
The Blood–Brain Barrier Model
Fig. 1 A illustrates the typical phenotypes of confluent
brain capillary ECs, cocultured for 12 d with astrocytes on
an insert coated with rat-tail collagen. Mitotracker colora-
tion shows an intense staining of the cell, indicating a large
amount of mitochondriae (Fig. 1 B). However, bodipy–
phallacidin staining reveals that a delicate fluorescent net-
work of actin filaments throughout the cytoplasm formed
prominent continuous bands at cell borders (Fig. 1 C).
Furthermore, ZO-1 is localized at sites of cell–cell contact
between ECs along the junctional complex (Fig. 1 D). This
continuous network of ZO-1 suggests that it is associated
with the tight junction barrier. These data, added to previ-
ously published results concerning the high electrical resis-
tance (500–800 V 3 cm2) and the low permeability (De-
houck et al., 1990a), support the fact that the coculture is a
legitimate model of the BBB.
LDL Internalization
Since LDL internalization in most cells is mediated prima-
rily by the LDL receptor, it was of interest to determine
the extent of internalization of LDL from the luminal sur-
face of brain capillary ECs. DiI-LDL was added to the lu-
minal compartment and remained in contact with the cells
for 45 min at 378C. Staining obtained with an immunofluo-
rescent microscope is shown in Fig. 2 B. DiI-LDL was
found as small, individual, discrete vesicles throughout the
cells. These results indicate that endocytotic pathways are
functional in these cells. The cellular accumulation of
gold–LDL was also examined by standard electron micros-
copy. Fig. 2, A and C, shows typical results demonstrating
the accumulation of gold–LDL in early endosomes and
Figure 1. Characterization of brain capillary EC monolayer grown on the upper face of a collagen-coated filter. (A) Phase contrast mi-
crograph of confluent brain capillary ECs. (B) Endothelial staining with mitochondrion-selective dye, Mitotracker CMX Ros. (C) Stain-
ing with F-actin probe, bodipy–phallacidin (Molecular Probes, Inc). (D) Localization of tight junction-associated protein ZO-1 to the
plasma membrane and nuclear staining by propidium iodine. Bar, 50 mm.Dehouck et al. LDL Transcytosis across the Blood–Brain Barrier 881 
in a multivesicular body. Furthermore, a coated pit could
be observed only rarely, and no accumulation of gold–
LDL was observed in lysosomes.
To determine whether degradation of LDL occurs in the
cells after internalization, degradation studies were carried
out using LDL for a 5-h incubation at 378C from the apical
surface (Fig. 3). 125I-LDL degradation by endothelial cell
monolayers was measured by the appearance of the io-
dine-free, TCA-soluble product released during incuba-
tion. No degradation of LDL occurred during the incuba-
tion period (Fig. 3 A). The functionality of the degradative
pathway was checked by carrying out the same experiment
using acetylated LDL (acLDL) instead of native LDL.
Acetylation of the lysine and arginine residues of the LDL
results in a modified LDL particle (acLDL) that is more
negative and has lost its ability to bind the (B,E) receptor
and the so-called scavenger receptor. When bindings of
LDL and acLDL were carried out at 48C, no difference
was observed between the binding of the two lipoproteins
at the luminal surface of the monolayer (4.7 ng/cm2 for
LDL versus 4.2 ng/cm2 for acLDL). As shown in Fig. 3 A,
acLDL is actively degraded by the brain capillary ECs.
This degradation is specific, since only unlabeled acLDL
can compete with acLDL (Fig. 3 B), indicating a receptor-
mediated degradation (scavenger receptor ligand). These
results demonstrate that in brain capillary ECs, the classic
degradation pathway (via lysosomes) is functional and
therefore that LDL is not directed to the lysosomes after
internalization.
Transport of LDL Across the Brain Capillary
EC Monolayer
From the experiments described above, it appears that
brain capillary ECs bind and internalize but do not de-
grade LDL. Transport experiments were performed to de-
fine the role of the LDL receptor. When 125I-LDL was
added to the luminal chamber of the culture, the progres-
sive transfer of these macromolecules across the cell
monolayer was observed during the 5-h incubation. The
transport was examined both in the absence and in the
presence of a 20-fold excess of unlabeled LDL. The toxic-
ity of high concentrations of LDL on the integrity of the
monolayer was assessed by calculating the permeability of
sucrose and insulin (Dehouck et al., 1992). No effect of
LDL concentrations up to 2 mg/ml was observed after an
8-h incubation (Pe 5 [0.52 6 0.19] 1023 cm/min for su-
crose, n 5 9). The amount of 125I-LDL (trichloro-acetic
precipitable) transported is expressed in terms of ng/cm2,
where the area refers to the surface area of the cells. Fig. 4
shows that the filter coated with rat-tail collagen and
maintained for 12 d with rat astrocytes is not a barrier for
the passage of LDL. An excess of unlabeled LDL com-
peted with the transport of LDL from the apical to the
basal membrane, although no evidence of saturation could
be detected in concentrations of LDL ranging from 10 to
100 mg/ml. Limitations in specific activity and quantities of
unlabeled LDL precluded examining concentrations of
LDL  . 100 mg/ml (125I-LDL; result not shown). Since ECs
Figure 2. Electron and fluorescence microscopy of ECs incubated with Au16nm and DiI-labeled LDL. After a 5-min incubation with gold
LDL at 378C, the tracer marks the luminal plasma membrane (A). After a 45-min incubation, the gold-labeled probe is mainly detected in
multivesicular bodies (C, arrow). Arrowheads indicate caveolar structure. (B) After 45 min of incubation, the fluorescent DiI-labeled
LDL is endocytosed and found as small vesicles throughout the cells. Bars: (A and C) 0.3 mm; (B) 30 mm.The Journal of Cell Biology, Volume 138, 1997 882
bind 4.7 ng of LDL/cm2 at 48C at the luminal concentra-
tion of 35 mg/ml of LDL and after 5-h transcytosis z100
ng/cm2 cross the monolayer, during the 5-h experiment,
z20 surface binding equivalents of LDL are transcytosed,
indicating that the transcytosis time is z15 min. To deter-
mine if transcytosed LDL is competent for rebinding to
the LDL receptor, degradation experiments of LDL by
the astrocytes of the coculture were performed for 16 h.
Our results showed that 3.27% of the transcytosed LDL
were degraded by the astrocytes. Only 0.8% of the LDL
was degraded if the astrocytes were not present during the
experiment. The specificity of the astrocyte degradation
was demonstrated by the fact that a 10-fold excess of unla-
beled LDL in the lower compartment reduced the degra-
dation of transcytosed LDL to 0.89%. These results indi-
cate that transcytosed LDL are competent for binding to
the LDL receptor located on astrocytes.
No specific binding on the abluminal face was observed
when labeled LDL was added in the lower chamber. But,
owing to the high nonspecific binding of LDL to the filter,
we cannot conclude whether the LDL receptor is specifi-
cally expressed or not at the abluminal face of brain capil-
lary ECs. There was no observed component of specific
LDL transport in the basal to apical direction. These re-
sults strongly indicate the existence of a specific pathway
operating in the transport of LDL from the apical to the
basal surfaces, but not in the reverse direction.
When the same transport experiments were performed
using radiolabeled acLDL instead of LDL in the luminal
compartment, no passage of acLDL was found over a 5-h
incubation. These results corroborate our conclusions with
regard to a specific transport of LDL across the mono-
layer. Furthermore, when the same experiments were car-
ried out with adrenal cortex ECs, a concentration-depen-
Figure 3. Degradation of LDL and acetylated LDL (acLDL) by
brain capillary ECs. (A) Specific degradation of 125I-LDL and
125I-acLDL. Degradation was performed at the concentration of
50 mg/ml for 5 h at 378C in the absence or the presence of a 20-
fold excess of related, unlabeled lipoproteins. (B) Competition
studies between labeled acLDL (*acLDL, 50 mg/ml;  ) with un-
labeled acLDL (acLDL8, 1 mg/ml;  ) and unlabeled LDL
(LDL8, 1 mg/ml;  ). Determination of the degradation was car-
ried out as described in Materials and Methods. Each point is a
mean of three different filters, and the curves are representative
of three series of experiments.
Figure 4. Transport of LDL across brain capillary EC monolay-
ers. Passage of 125I-LDL (ng/cm2) through collagen-coated filters
with (solid lines) or without (dashed line) brain capillary EC
monolayer was carried out at 378C. LDL was added to the upper
side of the filter (50 mg/ml 125I-LDL, 1 mg/ml unlabeled LDL).
Intact 125I-LDL transport from upper to lower sides of the filter
was assessed by counting in a g counter the acid-precipitable frac-
tions of the lower compartments. Specific transport (j) was cal-
culated by subtracting the radioactivity obtained in the presence
of native LDL (n) from that obtained in the absence of native
LDL (s). The data are expressed as ng of 125I-LDL transported
per cm2, which refers to the surface area of the cells. Each point is
a mean of three different filters, and the curves are representative
of seven series of independent experiments.Dehouck et al. LDL Transcytosis across the Blood–Brain Barrier 883 
dent, receptor-independent process was observed (results
not shown). From the experiments described above, the
specificity of the transport could be attributed to a recep-
tor-mediated process in brain capillary ECs.
To confirm that the LDL receptor is involved in this re-
ceptor-mediated transcytosis, transport experiments in the
presence of the C7-monoclonal antibody, known to inter-
act with the LDL receptor-binding domain and totally
block the binding of LDL to brain capillary ECs, were per-
formed. Fig. 5 shows that coincubations of LDL with in-
creasing concentrations of the C7 antibody, decrease the
rate of passage of the LDL through the monolayer. At the
concentration of 1 mg/ml, LDL transcytosis is totally abol-
ished. Control irrelevant IgG has no effect, suggesting
once more the involvement of the LDL receptor in this in-
tracellular traffic.
Fig. 6 compares the effect of temperature on LDL trans-
port from the apical to basal surfaces. A decrease in the in-
cubation temperature from 378 to 48C slightly affects the
passage of sucrose (Fig. 6 B), whereas a dramatic decrease
in the LDL transport through the monolayer is observed
(Fig. 6 A), indicating that LDL is directed to the abluminal
compartment by a transcellular route and that this trans-
port system requires active mechanisms such as receptor-
mediated transcytosis.
We have already demonstrated that the lipid require-
ment of astrocytes increases the expression of endothelial
cell LDL receptors (Dehouck et al., 1994). Is this upregu-
lation of the LDL receptor at the luminal face of brain
capillary ECs followed by an increase in LDL transcyto-
sis? To answer this question the following experiments
were carried out. Brain capillary ECs and astrocytes were
cocultured for 12 d in a medium containing 15% CS. 36 h
before the experiments, ECs were transferred onto other
astrocytes, and the astrocytes of the coculture were cul-
tured for 36 h in a medium containing 10% LPDS to mod-
ify the intracellular metabolism of these cells. After this
period, brain capillary ECs and cholesterol-depleted astro-
cytes in their conditioned medium were again cocultured
for 2 or 4 h at 378C (induction phase), and the binding at
48C and transcytosis experiments at 378C were performed.
Fig. 7 draws, after a 4-h induction, a parallel between the
Figure 5. Inhibition of LDL transport through EC monolayers by
the C7 monoclonal antibody. Specific 125I-LDL transport experi-
ment (35 mg/ml 125I-LDL, 700 mg/ml unlabeled LDL) was per-
formed as described in Fig. 4, legend, either in presence of C7-IgG,
1 mg/ml (d), 0.1 mg/ml (n), or AI-IgG, 1 mg/ml (h). Each point
is a mean of three different filters, and the curves are representa-
tive of three series of independent experiments.
Figure 6. Effect of temperature on the transport of 125I-LDL (A)
and sucrose (B) from apical to basal surfaces. Specific transport
of LDL was performed as described in Fig. 4, legend. Transport
of [14C]sucrose was expressed as the percentage of radioactivity
crossing the brain capillary EC monolayer from the apical to the
abluminal surfaces. 125I-LDL and sucrose transport were per-
formed both at 378 (h, s) and 48C (j, d). The data represent the
means of three filters, and the curves are representative of two
series of independent experiments.The Journal of Cell Biology, Volume 138, 1997 884
upregulation of the LDL receptor at the luminal surface of
the brain capillary ECs and the increase in the LDL trans-
cytosis across the monolayer, demonstrating once more
the involvement of the LDL receptor in the transcytosis.
These results were confirmed by the studies of the endocy-
tosis of DiI-LDL. Fig. 8 B shows an increase in the fluores-
cent signal in ECs cocultured for 4 h with cholesterol-
depleted astrocytes.
One of the characteristics of brain capillary ECs is the
paucity of clathrin-coated pits, known in other cell types to
mediate the endocytosis of LDL. Recently, Schnitzer et al.
(1994) have shown that a peripheral, continuous endothe-
lium possesses nonclathrin-coated vesicles (caveolae) that
seem to be involved in transcytosis. To study the involve-
ment of caveolae in LDL transcytosis at the brain level,
the effect of filipin on the endocytosis of LDL was studied.
Indeed it has been shown that cholesterol-binding agents
such as filipin cause the disassembly of caveolae. First, we
checked the toxicity of filipin on the integrity of the bar-
rier functions. No increase in sucrose permeability was ob-
served until 20 min of incubation of the EC monolayer in
the presence of concentrations of filipin ranging from 100
ng/ml to 3 mg/ml (Pe 5 [0.63 6 0.24] 1023 cm/min versus
[0.52 6 0.19] 1023 cm/min for sucrose; n 5 3). But, after 30
min incubation, a huge increase in the passage of sucrose
could be observed (Pe 5 [2.38 6 0.24] 1023 cm/min for su-
crose; n 5 6) reflecting an alteration of the barrier proper-
ties of the monolayer. For these reasons, preincubations
with filipin were carried out for 10 min only. The preincu-
bation of endothelium for 10 min with 3 mg/ml of filipin
before the addition of DiI-LDL resulted in a total inhibi-
tion of the fluorescent signal in the cells (Fig. 9 A). To rule
out the possibility that filipin inhibits the binding of LDL
to the cell surface, 125I-LDL binding to the cell surface of
the ECs was assessed for 1 h at 48C using confluent mono-
layers that were either preincubated or not with 3 mg/ml of
filipin for 10 min at 378C. We found no evidence for inter-
ference in the binding, indicating that filipin does not in-
teract with the binding of LDL to its receptor. Since filipin
is toxic for the integrity of the monolayer after 30 min and
transcytosis experiments lasted at least 3 h, the quantifica-
tion measurement of the effect of filipin was not possible.
The reversibility of the effect of filipin treatment on the
ECs was carried out. After filipin treatment and washings,
ECs were incubated for 1 h at 378C in serum-containing
medium and were then allowed to accumulate DiI-LDL
Figure 7. LDL transport after induction of LDL receptor expres-
sion on brain capillary ECs by cholesterol-depleted astrocytes.
Upregulation of LDL receptor on brain capillary ECs was per-
formed in four phases as described in Materials and Methods. On
the day of the experiment, brain capillary ECs in DME supple-
mented with 15% CS were cocultured for different times (1–4 h)
at 378C with cholesterol-depleted astrocytes in their 36-h incubat-
ing medium (induction phase). The increase of LDL receptor ex-
pression on ECs was studied by 125I-LDL binding at 48C (inset).
125I-LDL transport studies were performed at 378C, after 4 h in-
duction and .5 h, as described in Fig. 4, legend. The induction
phase was performed in the presence of either cholesterol-
depleted (d) or noncholesterol-depleted (h) astrocytes. The
data represent the means of three filters, and the curves are rep-
resentative of three series of independent experiments.
Figure 8. DiI-LDL endocytosis after induction of LDL receptor
expression on brain capillary ECs by cholesterol-depleted astro-
cytes. (A) Brain capillary ECs were incubated at 378C for 45 min
with DiI-LDL. After washing, the cells were fixed and processed
for fluorescent microscopy as described in Materials and Meth-
ods. (B) The same experiment was carried out with “upregulated
LDL receptor” ECs as described in Fig. 7, legend. Bar, 50 mm.Dehouck et al. LDL Transcytosis across the Blood–Brain Barrier 885 
for 45 min at 378C. As shown in Fig. 9 B, this short reversal
treatment resulted in the restoration of normal endocyto-
sis by the ECs, indicating that fundamental functions of
ECs are not altered by filipin.
The effect of filipin on clathrin-coated pits was also
checked using brain capillary ECs during the growing
phase. Under these conditions, LDL is classically interna-
lyzed by the clathrin pathway, where LDL is directed to ly-
sosomes for degradation and the cholesterol is used by the
cells. Fig. 9, C and D, demonstrates that in growing cells,
LDL endocytosis is not inhibited by filipin treatment. The
same results were obtained with differentiated ECs cocul-
tured for 12 d and fed with LPDS for 36 h to decrease their
cholesterol content. Furthermore, in these cases we can
note that the accumulation of DiI-LDL creates a perinu-
clear punctate signal consistent with its localization in ly-
sosomes. These results confirm that the coated vesicular
degradative pathway with its associated coated pits, endo-
somes, and lysosomes is not altered by filipin. The com-
partments of this pathway are functionally intact, unlike
the early stages of the noncoated vesicular pathway.
These results demonstrate that there is a shift from a re-
cycling LDL receptor to a transcytotic LDL receptor when
the cells are differentiated. Matter et al. (1993) reported
that ablating one of the LDL receptor internalization sig-
nals can transform the LDL receptor from a recycling to a
transcytotic trafficking pattern. To check whether such a
modification may occur in differentiated brain capillary
ECs, the sequences of the cytoplasmic tail of the LDL re-
ceptor required for basolateral sorting were analyzed and
compared to those of the recycling receptors for growing
brain capillary ECs. mRNA was extracted from these dif-
ferent cell lines, and the RT-PCR results show that a 245-bp
fragment is obtained with each culture condition studied.
Their sequences match the bovine LDL receptor perfectly
(100% identity), confirming that the consensus sequence
for the internalization signals is not altered in the differen-
tiated brain capillary ECs.
Discussion
In Vitro Blood–Brain Barrier
The availability of an in vitro model to study the passage
of macromolecules through the monolayers of brain capil-
lary endothelial cells on porous membranes enabled us to
investigate the characteristics of the passage of lipopro-
teins through endothelial monolayers. These ECs dis-
played: (a) tight junctions as visualized by actin and ZO-1
repartition; (b) an electrical resistance of .800 V 3 cm2;
(c) a low permeability for sucrose and insulin; (d) the pres-
ence of specific transporters (amino acids, glucose, propran-
olol [Dehouck et al., 1995]); (e) specific enzymatic activi-
ties of the BBB (g-glutamyl transpeptidase, monoamine
oxidase). Owing to the fact that a close correlation exists
between the values of the brain uptake index obtained in
vitro on our monolayers and those obtained in vivo with
the Oldendorf technique for a large number of drugs (De-
houck et al., 1995), the in vitro model resembles in vivo
features of animal ECs. Furthermore, we have recently
shown (Dehouck et al., 1994) that brain capillary ECs in
coculture express, in spite of the physiological concentra-
tions of lipoproteins in the incubation medium and the
tight apposition of ECs (Méresse et al., 1991), an LDL re-
ceptor as they do in vivo. Furthermore, we have found that
the fatty acid composition of cocultured ECs with astro-
cytes was markedly different from that of noncocultivated
ECs and that these fatty acid changes might be biologically
relevant, as they tended to make the fatty acid composi-
tion of brain capillary ECs more closely resemble that of
freshly isolated capillaries (Bénistant et al., 1995). To sum-
marize, our coculture enables us to apprehend, on an in
vitro model that closely mimics the in vivo conditions, the
cellular mechanism of LDL interaction with the BBB.
LDL Receptor Function at the Blood–Brain Barrier
What then is the function of this LDL receptor on the lu-
minal surface, and does it represent a true LDL receptor?
Since this receptor is expressed on brain capillary ECs at
confluence and in the presence of LDL in the medium
bathing either the basal or the apical surface, this receptor
is clearly not involved in regulating cholesterol biosynthe-
sis in ECs. Furthermore, as demonstrated (Méresse et al.,
1991; Dehouck et al., 1994), this luminal surface receptor
is likely to be a bona fide LDL receptor, as indicated by its
Figure 9. Effect of filipin on the endocytosis of LDL by brain
capillary ECs. (A) The cells were pretreated with filipin (3 mg/ml)
before the addition of DiI-LDL, and the endocytosis was per-
formed as described in the Fig. 8, legend. (B) Immediately after
filipin treatment, the cells were incubated in DME containing
20% CS for 30 min to reverse the effects of filipin before examin-
ing DiI-LDL endocytosis. (C and D) Endocytosis was carried out
with brain capillary ECs in growing phase without (C) or with
(D) pretreatment with filipin. Bar, 50 mm.The Journal of Cell Biology, Volume 138, 1997 886
saturability, its specificity, the ability of an anti-LDL re-
ceptor antibody to inhibit 125I-LDL binding, and its molec-
ular weight of 135.
Our results suggest that there is a specific mechanism
for the transport of LDL across the endothelial monolayer
from the blood to the brain side. This transport is a specific
transport mechanism that might be best explained by a pro-
cess of receptor-mediated transcytosis. Several points lead
us to this conclusion: (a) the transport is specific and unidi-
rectional; (b) the transcytosis is inhibited by the C7 mono-
clonal antibody, which is known to interact with the receptor-
binding domain (Beisiegel et al., 1981); (c) the transport
shows a temperature dependence similar to the process in-
volving receptor mediated internalization (Vasile et al.,
1983). It is also interesting to note that the transcytosis of
LDL from the luminal to the basal surface occurs in the
absence of a significant route involving its degradation.
The same results were obtained by Li et al. (1991) using
epithelial cells. Owing to the fact that amounts of LDL
and acLDL roughly bound to the luminal surface of the
monolayer at 48C, the nontranscytosis of acLDL after
their internalization in the ECs and their subsequent deg-
radation indicate that the lysosomal compartment is func-
tional in these cells, and reinforce the hypothesis that the
receptor mediated endocytotic pathway bypasses lysoso-
mal processing.
Furthermore, the transcytosis seems highly regulated.
First, it is receptor mediated and high concentration inde-
pendent. Second, the brain cells are able to regulate the
expression of the LDL receptor, as demonstrated by De-
houck et al. (1994). Indeed, the lipid requirement of astro-
cytes increases the number of LDL receptors at the lumi-
nal side of brain capillary ECs. That is why to investigate
the capacity of astrocytes to modulate LDL transcytosis,
the astrocytes of the coculture were preincubated in
LPDS, to decrease their lipid content. Under these condi-
tions, we observed that the LDL transcytosis parallels the
increase in the LDL receptor at the luminal side. Taken
together, these experiments indicate that LDL is transcy-
tosed through the brain endothelium by a receptor-medi-
ated mechanism and that the transcytosis could be regu-
lated by the surrounding astrocytes.
Our in vitro results are in agreement with the in vivo
clinical observations of patients with cerebrotendinuous
xanthomatosis (Salem et al., 1987). Indeed, excessive
amounts of cholestanol, the 5 c-dihydro derivative of cho-
lesterol, have been detected in the brain of patients with
this rare, inherited lipid storage disease. Affected patients
have progressive neurological dysfunctions (dementia, spi-
nal cord paresis, cerebellar ataxia), tendon xanthomas,
and premature atherosclerosis. Cholestanol accumulates
in patients because of overproduction in the liver as a con-
sequence of a genetic defect in bile acid synthesis (Salem
and Grundy, 1973). Consequently, the abnormal sterol de-
posits in the brain of patients with cerebrotendinuous xan-
thomatosis are believed to derive from plasma lipoproteins
passing through the BBB. The fact that apolipoprotein B
or an apolipoprotein B fragment, which increases out of
proportion to the other apolipoproteins and to lecithin
cholesterol acyl-transferase in the cerebrospinal fluid,
strongly suggests that this apolipoprotein serves to trans-
port sterols from the plasma to the brain in patients with
cerebrotendinuous xanthomatosis. Treatment of patients
with chenodeoxycholic acid not only reduced elevated ste-
rol concentration in the cerebrospinal fluid but also de-
creased the abnormal levels of apolipoprotein B in the
brain, suggesting that the function of the BBB returned to
normal. Our results demonstrating a “basal” transport of
LDL through brain capillary ECs and its upregulation by
the lipid composition of glial cells are in agreement with
the results observed in vivo in this disease.
In contrast, in peripheral vessels, Vasile et al. (1983), us-
ing an in situ perfusion of native LDL, showed that most
of the transendothelial transport of LDL is receptor inde-
pendent. Within the inherent limitations of this approach
and some uncertainties about the quantitative interpreta-
tion of the morphometric data obtained, the mechanism
and rate of transport of intact native LDL across the en-
dothelium in the peripheral organ has been the subject of
several in vitro studies (Navab et al., 1986; Langeler et al.,
1989). Despite the absence of functionally active LDL re-
ceptors due to contact inhibitor and physiological concen-
trations of plasma LDL in peripheral capillaries, there is a
significant transport of intact LDL across the endothe-
lium. These in vitro results confirm the in vivo observation
of Vasile et al. (1983) and describe a concentration-depen-
dent, receptor-independent process. Our data using adre-
nal cortex capillary ECs and aortic ECs are in agreement
with a transport of LDL independent of the simultaneous
addition of an excess amount of unlabeled LDL. From our
data, it is not possible to distinguish between a paracellular
route for the movement of LDL or a transcellular route in-
volving the formation of transient transendothelial chan-
nels. Thus, the normal peripheral confluent endothelium
functions are not related to the direct metabolism of LDL
but rather transport the particle intact, by mechanisms
unique to ECs, to the subendothelial space for metabolism
by other cells. This transcellular transport can deposit up
to twice the plasma concentration of LDL in the intersti-
tium of the aorta (Hoff et al., 1978; Smith and Ashall,
1983), demonstrating the nonregulation of this transport
and the possible appearance of sclerotic lesions.
Transcellular Mechanism of the Passage of LDL 
through the Brain Capillary EC Monolayer
The existence of receptor-mediated processes that bypass
lysosomes seems to be a feature of ECs. Indeed, as in con-
tinuous endothelia, ECs are linked to each other by junc-
tional complexes that constitute a major barrier to the bi-
directional exchange of macromolecules and specific receptors
play a significant role in the transendothelial transport of
plasma molecules to tissues. Several different albumin-
binding proteins have been identified on ECs; it appears
that gp30 and gp18 mediate the binding, endocytosis, and
degradation of modified albumin, whereas albondin (gp60)
mediates native albumin binding and subsequent transcy-
tosis (Schnitzer and Oh, 1994). Nevertheless, there is no
evidence of receptor-mediated transport of native albumin
in brain capillary endothelia (Pardridge et al., 1985). In the
same way, specific receptors of insulin are expressed on a
variety of ECs, and it has been shown that these receptors
are involved in insulin transport across ECs (King and
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crovessels in vivo (Van Houtten and Posner, 1979) or in
vitro (Franck and Pardridge, 1981) first suggests that the
pathway for insulin entry into the CNS involved transport
across the BBB. Furthermore, Franck et al. (1985) clearly
show in vivo that a saturable receptor was involved in the
brain uptake process. A more precise demonstration of
the transcytosis of blood-borne molecules was achieved
with an antibody directed against the ferrotransferrin re-
ceptor (OX-26). They have demonstrated that OX-26 se-
lectively targets the brain relative to organs such as the
kidneys, heart, or lungs. This statement is supported by the
capillary depletion technique experiments of Friden et al.
(1991, 1993), who have demonstrated the blood to brain
entry of OX-26 conjugated to methotrexate and nerve
growth factor, and by Broadwell et al. (1994), who have
performed cytochemical approaches using horseradish
peroxidase–OX-26. Using our model, we have provided
evidence for the transcytosis of iron-loaded transferrin
across the cerebral endothelium by means of a specific
transferrin receptor-mediated pathway (Descamps et al.,
1996). Furthermore, no intracellular degradation of trans-
ferrin was observed, indicating the occurrence of a path-
way through the cultured endothelium that bypasses the
lysosomal compartment.
The precise transcellular pathway for the passage of
blood-borne molecules across the BBB and into the CNS
has only recently begun to be elucidated (Villegas and
Broadwell, 1993; Broadwell et al., 1994). Owing to the fact
that early studies suggested a role for caveolae in endothe-
lial cell transport across the monolayer (Ghitescu et al.,
1986 ; Milici et al., 1987), to better appreciate possible ve-
sicular uptake and transport of LDL in brain capillary
ECs, we carried out experiments using filipin, a drug that
binds sterols, thereby disrupting caveolae (Severs and Si-
mons, 1986). But, since coated endocytic vesicles become
uncoated vesicles during the transport of ligands to the ly-
sosome, McGookey et al. (1983) found that coordinated
with the dissociation of the clathrin coat from endocytic
vesicles, the membranes became sensitive to the formation
of filipin–sterol complexes. To rule out the possibility that
the transcytotic vesicles may be derived from coated pits
and affected by filipin, whereas the coated vesicles on the
surface are protected, experiments were also carried out
using growing cells and differentiated cells depleted in
cholesterol. Under these conditions, we have shown that
filipin did not alter the classic degradation pathway of the
LDL receptor. In contrast, in differentiated cells still in
contact with lipoproteins, a complete inhibition of the en-
docytosis was achieved. The dramatic increase in the su-
crose permeability, after a 20-min incubation in the pres-
ence of filipin ruled out the possibility of performing
quantitative  studies on the effect of filipin on LDL transcy-
tosis, since these experiments last at least 5 h. In these con-
ditions, the huge increase in the paracellular transport
would hide the expected reduction in the transcellular
transport of LDL. But, added to our results demonstrating
the reversibility of a short treatment with filipin on en-
docytosis indicating that fundamental functions of ECs are
not altered by this drug, these results therefore suggest
that caveolae are likely to be involved in the potential
transport of LDL from the blood to the brain.
Although the capacity of caveolae to detach themselves
from the cell surface has been questioned (Bundgaard,
1983; Anderson, 1993), recent results strongly support the
involvement of caveolae in endocytosis (for review see
Lamaze and Schmid, 1995). Since LDL receptor ligands
rapidly dissociate at acid pH , tracking the pathway of the
receptor using conventional antireceptor antibodies (C7
monoclonal antibody) was not possible. The use of a chi-
meric receptor, consisting of the extracellular and trans-
membrane domains of the mouse IgG Fc receptor fused to
the LDL receptor cytoplasmic tail, is under investigation,
since this approach will permit the utilization of a high af-
finity Fab fragment of the mouse IgG antibody, 2.4 G2, a
well characterized probe that does not dissociate from the
receptor at pH values .4.0 (Mellman et al., 1984). Fur-
thermore, the fact that filipin stopped the fusion and/or in-
side internalization of caveolae in multivesicular struc-
tures argues in favor of a function of caveolae in
nonclathrin-dependent endocytosis and transcytosis, as al-
ready mentioned by Montesano et al. (1982), Milici et al.
(1987), and Tran et al. (1987). The work of Parton et al.
(1994), showing that caveolae are dynamic structures that
can be internalized into the cells leaves little doubt about
the function of caveolae in endocytosis.
In peripheral vessels, the characterization of caveolin-
rich membrane domains reveals known receptors for mod-
ified LDL (scavenger receptor, CD 36, and RAGE) and
multiple GPI-linked proteins, but the receptor for native
LDL was not mentioned (Lisanti et al., 1994). This was not
surprising, owing to the fact that the LDL receptor is down
regulated in physiological conditions in peripheral vessels.
In brain capillaries, in spite of the high concentration of li-
poproteins, the LDL receptor is not down regulated. It is
not localized as in growing cells or cholesterol-depleted
differentiated cells in coated pits but in caveolae. The bal-
ance between distinct endocytic pathways can be shifted in
response to cellular requirements (in this case the need of
cholesterol for the ECs), suggesting that these pathways
could be regulated differently. As shown by Matter et al.
(1993), the change from a recycling to a transcytotic recep-
tor could have been the consequence of the ablation of
one of the internalization signals of the cytoplasmic do-
main of the receptor. Our results demonstrated that LDL
receptor messengers in growing brain capillary ECs (recy-
cling receptor), or differentiated cells (transcytotic recep-
tor) that are 100% identical, ruled out this hypothesis. But,
as demonstrated for the polymeric IgA receptor, the shift
of an endocytotic receptor to a transcytotic receptor could
also be due to posttranslational modifications of the cyto-
plasmic domain of the receptor. Indeed, Casanova et al.
(1990) and Aroeti and Mostow (1994) demonstrated that
phosphorylation of Ser664 inactivates the endocytotic sig-
nal and permits the polymeric immunoglobulin receptor to
be transcytosed.
Recent results have provided new tools that allow de-
tailed study of caveolar dynamics. Parton et al. (1994)
show that internalization of caveolae may be a regulated
process, since increased phosphorylation due to phos-
phatase inhibition induces the removal of caveolae from
the cell surface, whereas decreased kinase activity inhibits
the internalization process. Eker et al. (1994) pinpoint the in-
volvement of cAMP since this second messenger appears
to upregulate clathrin-independent endocytosis selectivelyThe Journal of Cell Biology, Volume 138, 1997 888
at the apical surface of polarized ECs. The hormonal regu-
lation of caveolae internalization has been shown by
Smart et al. (1995), suggesting that molecules added to the
luminal surface of the endothelium could modulate the en-
docytosis via caveolae. Our results demonstrating an in-
crease in transcytosis, when the astrocytes of the coculture
were depleted in cholesterol, suggest that endocytosis via
caveolae and transcytosis could, in part, be regulated by
signal molecules secreted by astrocytes and then acting at
the abluminal face of brain capillary ECs. These results
provide evidence that the brain blood vessel endothelium
may not be as inert a barrier as has been assumed. Appro-
priate stimulus can increase endocytotic activity in these
cells.
In summary, taken together, these experiments indicate
that LDL is transcytosed through the BBB via a receptor-
mediated mechanism in specialized endocytic vesicles that
avoid fusion with lysosomes. In contrast to other ECs in
the body, these highly differentiated cells regulate the en-
try of lipoproteins into the brain. Furthermore, the influ-
ence of astrocytes on the expression of the LDL receptor
and the rate of LDL transcytosis suggest the existence of
focal differences in lipoprotein influx, which may depend
on the lipid state of astrocytes. The BBB cannot be consid-
ered as a rigid and impermeable structure protecting the
brain, but as a dynamic interface able to modify its perme-
ability to the specific needs of certain areas of the brain.
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